Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18448
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRibas, Antoni-
dc.contributor.authorDummer, Reinhard-
dc.contributor.authorPuzanov, Igor-
dc.contributor.authorVanderWalde, Ari-
dc.contributor.authorAndtbacka, Robert H I-
dc.contributor.authorMichielin, Olivier-
dc.contributor.authorOlszanski, Anthony J-
dc.contributor.authorMalvehy, Josep-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorFernandez, Eugenio-
dc.contributor.authorKirkwood, John M-
dc.contributor.authorGajewski, Thomas F-
dc.contributor.authorChen, Lisa-
dc.contributor.authorGorski, Kevin S-
dc.contributor.authorAnderson, Abraham A-
dc.contributor.authorDiede, Scott J-
dc.contributor.authorLassman, Michael E-
dc.contributor.authorGansert, Jennifer-
dc.contributor.authorHodi, F Stephen-
dc.contributor.authorLong, Georgina V-
dc.date.accessioned2018-08-30T06:04:42Z-
dc.date.available2018-08-30T06:04:42Z-
dc.date.issued2017-09-07-
dc.identifier.citationCell 2017; 170(6): 1109-1119.e10-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18448-
dc.description.abstractHere we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurred. Confirmed objective response rate was 62%, with a complete response rate of 33% per immune-related response criteria. Patients who responded to combination therapy had increased CD8+ T cells, elevated PD-L1 protein expression, as well as IFN-γ gene expression on several cell subsets in tumors after talimogene laherparepvec treatment. Response to combination therapy did not appear to be associated with baseline CD8+ T cell infiltration or baseline IFN-γ signature. These findings suggest that oncolytic virotherapy may improve the efficacy of anti-PD-1 therapy by changing the tumor microenvironment. VIDEO ABSTRACT.-
dc.language.isoeng-
dc.subjectT lymphocytes-
dc.subjectanti-PD-1-
dc.subjectbiomarkers-
dc.subjectcytotixic-
dc.subjectinterferon gamma-
dc.subjectMelanoma-
dc.subjectoncolytic immunotherapy-
dc.subjectoncolytic viruses-
dc.subjectpembrolizumab-
dc.subjecttalimogene laherparepvec-
dc.subjecttumor-
dc.subjecttumor microenvironment-
dc.titleOncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.-
dc.typeJournal Article-
dc.identifier.journaltitleCell-
dc.identifier.affiliationUniversity of Utah Huntsman Cancer Institute, Salt Lake City, UT, USAen
dc.identifier.affiliationHospital Clinic i Provincial de Barcelona, Barcelona, Spainen
dc.identifier.affiliationHopitaux Universitaires de Genève, Geneva, Switzerlanden
dc.identifier.affiliationUniversity of California at Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USAen
dc.identifier.affiliationCentre Hospitalier Universitaire Vaudois, LaUSAnne, Switzerlanden
dc.identifier.affiliationUniversity Hospital of Zurich, Zurich, Switzerlanden
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationThe West Clinic, Memphis, TN, USAen
dc.identifier.affiliationDana-Farber Cancer Institute, Boston, MA, USAen
dc.identifier.affiliationAmgen Inc., ThoUSAnd Oaks, CA, USAen
dc.identifier.affiliationMerck & Co., Inc., Kenilworth, NJ, USAen
dc.identifier.affiliationRoswell Park Cancer Institute, Buffalo, NY, USAen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationAmgen Inc., South San Francisco, CA, USAen
dc.identifier.affiliationThe University of Chicago School of Medicine, Chicago, IL, USAen
dc.identifier.affiliationUniversity of Pittsburgh Cancer Institute and Hillman UPMC Cancer Center, Pittsburgh, PA, USAen
dc.identifier.affiliationFox Chase Cancer Center, Philadelphia, PA, USAen
dc.identifier.affiliationMelanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, NSW, Australiaen
dc.identifier.doi10.1016/j.cell.2017.08.027-
dc.identifier.orcid0000-0002-3898-950X-
dc.identifier.pubmedid28886381-
dc.type.austinClinical Trial, Phase I-
dc.type.austinJournal Article-
local.name.researcherCebon, Jonathan S
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.